Syed Asif Shah, MD
Internal Medicine · Sioux Falls, SDNPI 1275514218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Mylan Specialty L.p. at 44.8% of the total. Reporting peaked in 2024 at $208 and has fallen 85.3% since, to $31 in 2025.
Across 43 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$329
- Merck$94
- Takeda Pharmaceuticals U.S.A., Inc.$59
- Harmony Biosciences LLC$41
- Daiichi Sankyo Inc.$36
- Grifols USA, LLC$36
- plus $142 from 8 others
What the payments were for
- Food & beverage$735100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 18 | $329 |
| Merck | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Harmony Biosciences LLC | 2 | $41 |
| Daiichi Sankyo Inc. | 3 | $36 |
| Grifols USA, LLC | 2 | $36 |
| Baxter Healthcare | 2 | $35 |
| AbbVie | 2 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Pfizer | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| GSK | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$735 in reported general payments places this provider in the 80th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $50,902 |
| OzempicSemaglutide | 44 | $48,135 |
| Xtampza ErOxycodone Myristate | 25 | $46,245 |
| JardianceEmpagliflozin | 38 | $29,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $10,872 |
| Potassium Chloride | 139 | $3,029 |
| SynthroidLevothyroxine Sodium | 34 | $2,504 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $2,474 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 85 | $2,292 |
| Levothyroxine Sodium | 278 | $2,217 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,145 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $2,098 |
| Rosuvastatin Calcium | 55 | $1,938 |
| Oxycodone Hcl | 100 | $1,836 |
| CholestyramineCholestyramine (With Sugar) | 23 | $1,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $50,902106 claims |
| Boehringer IngelheimJardiance | $17 | $29,96638 claims |
| GSKTrelegy Ellipta | $12 | $10,87218 claims |
| AbbVieSynthroid, Armour Thyroid | $23 | $3,37553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Sioux Falls
- Janell PowellSioux Falls$7K
- Maaz BadshahSioux Falls$6K
- Wendy VetterSioux Falls$5K
- Jeffrey HeierSioux Falls$4K
- Shristi Upadhyay BanskotaSioux Falls$3K
- Anup ShresthaSioux Falls$1K
- Whitnee OttoSioux Falls$1K
- Alla ZamulkoSioux Falls$969
- Chirag PatelSioux Falls$924
- Brooke MadsonSioux Falls$760
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.